Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ManNAc

Phase 2Small molecule

LLeadiant Biosciences, Inc.

ManNAc is one of 69 small molecule programs targeting Myopathy. It is currently in Phase 2.

2

Indications

4

Total Trials

2

Active Trials

68

Competitors

Pipeline

Status by Indication[3][1]

Indication

MyopathyActive, not recruiting

Focal Segmental GlomerulosclerosisActive, not recruiting

MyopathyPhase 1

Active, not recruiting

Focal Segmental GlomerulosclerosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

51 competitors in Focal Segmental Glomerulosclerosis

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Empaveli

Apellis Pharmaceuticals

Accutane

CConrado Roberto Hoffmann Filho

Glucophage

Rituxan

Avapro

Filspari

TTravere Therapeutics, Inc.

Cyclosporin

Simulect

Cellcept

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Focal Segmental Glomerulosclerosis

NCT06664814

Clinical

Trials by Indication[1]

Myopathy3 trials

An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy

Completed·NNational Human Genome Research Institute (NHGRI)·Phase 2·NCT02346461·12 enrolled

Multi-Center Study of ManNAc for GNE Myopathy

Active, not recruiting·LLeadiant Biosciences, Inc.·Phase 2·NCT04231266·54 enrolled

Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)

Completed·NNational Human Genome Research Institute (NHGRI)·Phase 1·NCT01634750·26 enrolled

Focal Segmental Glomerulosclerosis1 trial

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

Recruiting·NNational Human Genome Research Institute (NHGRI)·Phase 2·NCT06664814·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ManNAc. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ManNAc compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ManNAc. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Leadiant Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLeadiant Biosciences, Inc.

Related News